Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EZH2 | Q15910 | 13/20 | 1.00 |
| ▸ | EZH1 | Q92800 | 12/20 | 0.79 |
| ▸ | EED | O75530 | 4/20 | 0.79 |
| ▸ | RBBP4 | Q09028 | 4/20 | 0.79 |
| ▸ | SUZ12 | Q15022 | 4/20 | 0.79 |
| ▸ | AEBP2 | Q6ZN18 | 4/20 | 0.79 |
| ▸ | RBBP7 | Q16576 | 3/20 | 0.79 |
| ▸ | PRMT3 | O60678 | 2/20 | 0.79 |
| ▸ | SETD7 | Q8WTS6 | 2/20 | 0.79 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17734431 | 1.00 | EZH2 (1.00) | EZH2EZH1EEDRBBP4SUZ12 | |
| SCHEMBL17734355 | 0.94 | EZH2 (0.89) | EZH2EZH1EEDRBBP4SUZ12 | |
| SCHEMBL23863720 | 0.93 | EZH2 (0.88) | EZH2EZH1EEDRBBP4SUZ12 | |
| SCHEMBL10255922 | 0.92 | EZH2 (0.88) | EZH2EZH1EEDRBBP4SUZ12 | |
| SCHEMBL17734375 | 0.90 | EZH2 (0.82) | EZH2EZH1EEDRBBP4SUZ12 | |
| SCHEMBL17734470 | 0.90 | EZH2 (0.81) | EZH2EZH1EEDRBBP4SUZ12 | |
| SCHEMBL12684042 | 0.90 | EZH2 (0.81) | EZH2EZH1EEDRBBP4SUZ12 | |
| SCHEMBL17734376 | 0.89 | EZH2 (0.80) | EZH2EZH1EEDRBBP4SUZ12 | |
| SCHEMBL12180659 | 0.88 | EZH1 (1.00) | EZH2EZH1EEDRBBP4SUZ12 | |
| SCHEMBL17734373 | 0.87 | EZH2 (0.78) | EZH2EZH1EEDRBBP4SUZ12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12636283-B2 | Inhibition of PRC2 subunits to treat eye disorders | FONDATION ASILE DES AVEUGLES (CH) | 2026-05-26 | — | — | US | claimed |
| US-20250311689-A1 | SEEDLING GERMINATION AND GROWTH CONDITIONS | PIONEER HI-BRED INTERNATIONAL, INC. (US) | 2025-10-09 | — | — | US | claimed |
| WO-2025059442-A1 | MODULATING PLANT RESPONSES TO STRESS AND GROWTH WITH CHEMICALS | REMOTE EPIGENETICS INC. (US) | 2025-03-20 | — | — | WO | claimed |
| CN-119326889-A | PHGDH inhibitor and application thereof in treatment of disseminated tumor cells | 复旦大学附属中山医院 | 2025-01-21 | — | — | CN | claimed |
| US-20240408081-A1 | NOVEL SYNERGISTIC COMBINATIONS AND METHODS OF USE THEREOF FOR TREATING CANCERS | INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE - INSERM (FR) | 2024-12-12 | — | — | US | claimed |
| EP-4423254-A1 | COMPOSITIONS AND METHODS FOR PROMOTING IN VITRO MATURATION OF CELLS | Memorial Sloan Kettering Cancer Center (US) | 2024-09-04 | — | — | EP | claimed |
| US-20240279600-A1 | COMPOSITIONS AND METHODS FOR PROMOTING IN VITRO MATURATION OF CELLS | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2024-08-22 | — | — | US | claimed |
| EP-4401719-A1 | NOVEL SYNERGISTIC COMBINATIONS AND METHODS OF USE THEREOF FOR TREATING CANCERS | UNIVERSITE DE BORDEAUX (FR) | 2024-07-24 | — | — | EP | claimed |
| WO-2023076554-A9 | COMPOSITIONS AND METHODS FOR PROMOTING IN VITRO MATURATION OF CELLS | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2024-07-11 | — | — | WO | claimed |
| CN-117979962-A | Novel synergistic combinations for treating cancer and methods of use thereof | 波尔多大学 | 2024-05-03 | — | — | CN | claimed |
| EP-3823671-B1 | INHIBITION OF PRC2 SUBUNITS TO TREAT EYE DISORDERS | FOND ASILE DES AVEUGLES (CH) | 2024-02-07 | — | — | EP | claimed |
| CN-117503930-A | Application of PRC2 complex as target in developing medicine for preventing and treating neurodegenerative diseases or central nerve injury diseases | 北京干细胞与再生医学研究院 | 2024-02-06 | — | — | CN | claimed |
| CN-116510024-A | Composition, preparation method and application thereof | 上海复东生物医药有限责任公司 | 2023-08-01 | — | — | CN | claimed |
| US-20230123585-A1 | COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING CANCER USING DEUBIQUITINASE INHIBITORS | UNIV CHICAGO (US) | 2023-04-20 | — | — | US | claimed |
| WO-2023056236-A1 | SEEDLING GERMINATION AND GROWTH CONDITIONS | PIONEER HI-BRED INTERNATIONAL, INC. (US) | 2023-04-06 | — | — | WO | claimed |
| WO-2023041674-A1 | NOVEL SYNERGISTIC COMBINATIONS AND METHODS OF USE THEREOF FOR TREATING CANCERS | Universite de Bordeaux (FR) | 2023-03-23 | — | — | WO | claimed |
| EP-4151208-A1 | NOVEL SYNERGISTIC COMBINATIONS AND METHODS OF USES THEREOF FOR TREATING CANCERS | UNIVERSITE DE BORDEAUX (FR) | 2023-03-22 | — | — | EP | claimed |
| US-20220349015-A1 | DIAGNOSIS AND TREATMENT OF THYROID CANCER | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 2022-11-03 | — | — | US | claimed |
| US-20220193056-A1 | COMPOSITIONS AND METHODS OF TREATING PIK3CA HELICAL DOMAIN MUTANT CANCERS | CASE WESTERN RESERVE UNIVERSITY | 2022-06-23 | — | — | US | claimed |
| EP-4728051-A1 | STANDARDISING PLURIPOTENT STEM CELLS | United Kingdom Research and Innovation (GB) | 2026-04-22 | — | — | EP | disclosed |
| US-20250311689-A1 | SEEDLING GERMINATION AND GROWTH CONDITIONS | PIONEER HI-BRED INTERNATIONAL, INC. (US) | 2025-10-09 | — | — | US | disclosed |
| US-20250304585-A1 | SULFAMATE BASED COVALENT LIGAND-DIRECTED RELEASE (COLDR) COMPOUNDS | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2025-10-02 | — | — | US | disclosed |
| US-12377092-B2 | Polycomb inhibitors and uses thereof | FONDAZIONE ISTITUTO FIRC DI ONCOLOGIA MOLECOLARE (IFOM) (IT) | 2025-08-05 | — | — | US | disclosed |
| EP-4540249-A1 | SULFAMATE BASED COVALENT LIGAND-DIRECTED RELEASE (COLDR) COMPOUNDS | Yeda Research and Development Co. Ltd (IL) | 2025-04-23 | — | — | EP | disclosed |
| US-12274697-B2 | Compositions and methods for treating EZH2-mediated cancer | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2025-04-15 | — | — | US | disclosed |
| WO-2025059442-A1 | MODULATING PLANT RESPONSES TO STRESS AND GROWTH WITH CHEMICALS | REMOTE EPIGENETICS INC. (US) | 2025-03-20 | — | — | WO | disclosed |
| CN-119326889-A | PHGDH inhibitor and application thereof in treatment of disseminated tumor cells | 复旦大学附属中山医院 | 2025-01-21 | — | — | CN | disclosed |
| WO-2024256607-A1 | STANDARDISING PLURIPOTENT STEM CELLS | UNITED KINGDOM RESEARCH AND INNOVATION (GB) | 2024-12-19 | — | — | WO | disclosed |
| US-20240408081-A1 | NOVEL SYNERGISTIC COMBINATIONS AND METHODS OF USE THEREOF FOR TREATING CANCERS | INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE - INSERM (FR) | 2024-12-12 | — | — | US | disclosed |
| US-12161635-B2 | Compositions and methods of treating PIK3CA helical domain mutant cancers | CASE WESTERN RESERVE UNIVERSITY (US) | 2024-12-10 | — | — | US | disclosed |
| EP-4423254-A1 | COMPOSITIONS AND METHODS FOR PROMOTING IN VITRO MATURATION OF CELLS | Memorial Sloan Kettering Cancer Center (US) | 2024-09-04 | — | — | EP | disclosed |
| US-20240279600-A1 | COMPOSITIONS AND METHODS FOR PROMOTING IN VITRO MATURATION OF CELLS | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2024-08-22 | — | — | US | disclosed |
| EP-4401719-A1 | NOVEL SYNERGISTIC COMBINATIONS AND METHODS OF USE THEREOF FOR TREATING CANCERS | UNIVERSITE DE BORDEAUX (FR) | 2024-07-24 | — | — | EP | disclosed |
| WO-2023076554-A9 | COMPOSITIONS AND METHODS FOR PROMOTING IN VITRO MATURATION OF CELLS | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2024-07-11 | — | — | WO | disclosed |
| CN-112481192-B | Chemical small molecule composition and method for directly reprogramming in vitro and in vivo chemically induced fibroblast into hepatocyte | 海门雨霖细胞科技有限责任公司 | 2024-05-28 | — | — | CN | disclosed |
| CN-117979962-A | Novel synergistic combinations for treating cancer and methods of use thereof | 波尔多大学 | 2024-05-03 | — | — | CN | disclosed |
| US-20240139326-A1 | METHACRYLAMIDES PROTEIN BINDERS AND USES THEREOF | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2024-05-02 | — | — | US | disclosed |
| CN-113444086-B | Ezh2 inhibitors and uses thereof | 达纳-法伯癌症研究所股份有限公司 | 2024-04-30 | — | — | CN | disclosed |
| US-20240110230-A1 | BIOMARKERS FOR CANCER TREATMENT | FOUNDATION MEDICINE, INC. (US) | 2024-04-04 | — | — | US | disclosed |
| WO-2023242845-A1 | SULFAMATE BASED COVALENT LIGAND-DIRECTED RELEASE (CoLDR) COMPOUNDS | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2023-12-21 | — | — | WO | disclosed |
| EP-4291902-A2 | BIOMARKERS FOR CANCER TREATMENT | Foundation Medicine, Inc. (US) | 2023-12-20 | — | — | EP | disclosed |
| US-20230310421-A1 | MOLECULES FOR USE IN THE TREATMENT OF VIRAL INFECTIONS | ISTITUTO EUROPEO DI ONCOLOGIA S.R.L. (IT) | 2023-10-05 | — | — | US | disclosed |
| US-20230123585-A1 | COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING CANCER USING DEUBIQUITINASE INHIBITORS | UNIV CHICAGO (US) | 2023-04-20 | — | — | US | disclosed |
| US-20230114294-A1 | COMPOSITIONS AND METHODS FOR TREATING EZH2-MEDIATED CANCER | ICAHN SCHOOL MED MOUNT SINAI (US) | 2023-04-13 | — | — | US | disclosed |
| WO-2023056236-A1 | SEEDLING GERMINATION AND GROWTH CONDITIONS | PIONEER HI-BRED INTERNATIONAL, INC. (US) | 2023-04-06 | — | — | WO | disclosed |
| WO-2023041674-A1 | NOVEL SYNERGISTIC COMBINATIONS AND METHODS OF USE THEREOF FOR TREATING CANCERS | Universite de Bordeaux (FR) | 2023-03-23 | — | — | WO | disclosed |
| EP-4151208-A1 | NOVEL SYNERGISTIC COMBINATIONS AND METHODS OF USES THEREOF FOR TREATING CANCERS | UNIVERSITE DE BORDEAUX (FR) | 2023-03-22 | — | — | EP | disclosed |
| EP-4135679-A1 | MOLECULES FOR USE IN THE TREATMENT OF VIRAL INFECTIONS | Istituto Europeo di Oncologia S.r.l. (IT) | 2023-02-22 | — | — | EP | disclosed |
| CN-112870366-B | New application of EZH2 inhibitor in preparation of tumor treatment medicines | 江苏恒瑞医药股份有限公司 | 2023-01-24 | — | — | CN | disclosed |
| CN-112870367-B | Use of an EZH2 inhibitor, a CDK4/6 inhibitor and a MEK inhibitor for the preparation of a medicament for the treatment of tumors | 江苏恒瑞医药股份有限公司 | 2023-01-20 | — | — | CN | disclosed |
| US-20230014430-A1 | Methods and Compositions for Generating Functionally Mature Beta Cells and Uses Thereof | WASHINGTON UNIVERSITY (US) | 2023-01-19 | — | — | US | disclosed |
| US-11510920-B2 | Compositions and methods for treating EZH2-mediated cancer | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2022-11-29 | — | — | US | disclosed |
| US-20220349015-A1 | DIAGNOSIS AND TREATMENT OF THYROID CANCER | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 2022-11-03 | — | — | US | disclosed |
| CN-115227695-A | Combination therapy comprising targeted therapeutic agents | 特瓦(ABC)有限责任公司 | 2022-10-25 | — | — | CN | disclosed |
| WO-2022174234-A2 | BIOMARKERS FOR CANCER TREATMENT | FOUNDATION MEDICINE, INC. (US) | 2022-08-18 | — | — | WO | disclosed |
| US-20220257777-A1 | HSP90-BINDING CONJUGATES AND COMBINATION THERAPIES THEREOF | TVA (ABC), LLC | 2022-08-18 | — | — | US | disclosed |
| EP-4017527-A1 | COMBINATION THERAPY OF A T CELL THERAPY AND AN ENHANCER OF ZESTE HOMOLOG 2 (EZH2) INHIBITOR AND RELATED METHODS | Juno Therapeutics, Inc. (US) | 2022-06-29 | — | — | EP | disclosed |
| US-20220193056-A1 | COMPOSITIONS AND METHODS OF TREATING PIK3CA HELICAL DOMAIN MUTANT CANCERS | CASE WESTERN RESERVE UNIVERSITY | 2022-06-23 | — | — | US | disclosed |
| CN-114555112-A | Combination therapy of T cell therapy and ZESTE enhancer homolog 2(EZH2) inhibitors and related methods | 朱诺治疗学股份有限公司 | 2022-05-27 | — | — | CN | disclosed |
| EP-3989980-A1 | HSP90-BINDING CONJUGATES AND COMBINATION THERAPIES THEREOF | Tarveda Therapeutics, Inc. (US) | 2022-05-04 | — | — | EP | disclosed |
| CN-114126624-A | HSP90 binding conjugates and combination therapies thereof | 塔弗达治疗有限公司 | 2022-03-01 | — | — | CN | disclosed |
| CN-114126624-A | HSP90 binding conjugates and combination therapies thereof | 塔弗达治疗有限公司 | 2022-03-01 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12274697-B2 | Compositions and methods for treating EZH2-mediated cancer | EZH2, EZH1, EED | EZH2 1/4885EZH1 2/4885EED 3/4885 |
| US-12636283-B2 | Inhibition of PRC2 subunits to treat eye disorders | EZH2, EZH1, EED | EZH2 1/4885EZH1 2/4885EED 3/4885 |
| US-11510920-B2 | Compositions and methods for treating EZH2-mediated cancer | EZH2, EZH1, EED | EZH2 1/4885EZH1 2/4885EED 3/4885 |
| US-12377092-B2 | Polycomb inhibitors and uses thereof | BMI1, EED, EZH2 | EZH2 3/4885EZH1 7/4885EED 2/4885 |
| US-20240139326-A1 | METHACRYLAMIDES PROTEIN BINDERS AND USES THEREOF | STAMBP, HSPBP1, ECPAS | EZH2 1521/4885EZH1 2038/4885EED 2797/4885 |
| US-20230310421-A1 | MOLECULES FOR USE IN THE TREATMENT OF VIRAL INFECTIONS | IRF3, EIF2AK2, MAVS | EZH2 37/4885EZH1 49/4885EED 513/4885 |
| US-20220257777-A1 | HSP90-BINDING CONJUGATES AND COMBINATION THERAPIES THEREOF | HSP90B1, HSP90AB1, HSP90AB2P | EZH2 3494/4885EZH1 3673/4885EED 2594/4885 |
| US-20230114294-A1 | COMPOSITIONS AND METHODS FOR TREATING EZH2-MEDIATED CANCER | EZH2, EZH1, EED | EZH2 1/4885EZH1 2/4885EED 3/4885 |
| US-20250304585-A1 | SULFAMATE BASED COVALENT LIGAND-DIRECTED RELEASE (COLDR) COMPOUNDS | CASR, NPSR1, GSR | EZH2 3503/4885EZH1 3419/4885EED 2069/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.